Mimopath™-based vaccine delivery

Abstract

Vaccines are considered one of the most valuable public health intervention tools. Nevertheless, the performance of many existing vaccines is far from optimal and there are still diseases for which no vaccine is available. A key issue in the development of improved and new vaccines is safety, since most vaccines are given to healthy individuals. In order to improve safety profiles, the use of well-defined (recombinant) purified antigens for the generation of subunit vaccines has become leading in vaccine development programs. In addition, there is an increasing interest to explore other modes of vaccine administration besides the use of needles. Since purified soluble antigens are usually poorly immunogenic, even more when delivered through the mucosal (nasal, oral) routes, the addition of safe adjuvants to increase the efficacy of vaccines is needed.